SAN FRANCISCO, March 02, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is facing headwinds on multiple fronts, including disappointing sales figures, ongoing legal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback